Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:August 27, 2018
End Date:March 1, 2021
Contact:Virgil Rose, MD
Email:virgil.Rose@ppdi.com
Phone:+1 919 456 6615

Use our guide to learn which trials are right for you!

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)

This study in patients with relapsed/refractory follicular lymphoma who have undergone at
least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a
day (BID) in a "one week on, one week off" schedule.

Patients will be evaluated for objective response, Duration of Response (DOR), Progression
Free Survival (PFS), Clinical Benefit Rate (CBR), Overall survival (OS), safety and
tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and changes in health related
quality of life. Patients may receive treatment until disease progression, death,
unacceptable toxicity, or withdrawal of consent. An independent data safety monitoring
committee (iDMC) will evaluate the data pertaining to the futility and decide whether the
study should stop or continue to the second stage. If the study continues to the second
stage, a total of 139 patients will be studied.

Inclusion Criteria:

- Is able to understand and voluntarily sign an informed consent document before any
study related assessments/procedures are conducted.

- Has histologically confirmed Grade 1, 2, or 3a follicular lymphoma.

- Has follicular lymphoma that has relapsed after (progressed after 6 months from the
start of therapy) or is refractory to the last line of therapy (no response or
progression within 6 months from the start of therapy) and needs treatment (must have
at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3
cm in its longest diameter).

- Female patients must fulfil the following criteria:

a. Be of non-childbearing potential, defined as follows: i. Postmenopausal (ie, ≥ 1
year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1
month prior to Screening)

- Male patients must agree not to donate sperm starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

- Use highly effective forms of birth control (women of childbearing potential only),
which include the following:

i. Consistent and correct use of established oral contraception ii. Established
intrauterine device or intrauterine system iii. Barrier methods of contraception:
condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal
foam/gel/film/cream/suppository.

- Female patients must agree not to breastfeed starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

- Male patients and their female spouse/partners who are of childbearing potential must
use highly effective contraception methods consisting of 2 forms of birth control (at
least 1 of which must be a barrier method) from the time of Screening, throughout the
study, and until after 90 days following the last dose.

- Male patients must agree not to donate sperm starting from the time of Screening,
throughout the study, and until after 90 days following the last dose.

Exclusion Criteria:

- Has diagnosis of Grade 3b follicular lymphoma, or transformation to diffuse large
B-cell lymphoma

- Has a history of central nervous system lymphoma (either primary or secondary).

- Has had prior treatment with abexinostat.

- Has had allogeneic stem cell transplant within the last 6 months, or autologous stem
cell transplant within the last 3 months before enrollment

- Has any types of cardiac impairment at the time of enrollment

- Has received any investigational medication within 30 days or 5 half-lives prior to
Day 1, whichever is longer

- Has prior history of malignancies, other than follicular lymphoma, unless the patient
has been free of the disease for ≥ 3 years
We found this trial at
9
sites
Park Ridge, Illinois 60068
Principal Investigator: Jacob Bitran, MD
Phone: 847-410-0667
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Arlington, Texas 76012
Principal Investigator: Alfred DiStefano, MD
Phone: 817-261-4906
?
mi
from
Arlington, TX
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: Morton Coleman, MD
Phone: 516-488-2918
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
3991 Dutchmans Lane
Louisville, Kentucky 40202
Principal Investigator: Don Stevens, MD
Phone: 502-899-3366
?
mi
from
Louisville, KY
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Karen Haglof, MD
Phone: 212-689-6791
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Connie Batlevi, MD
Phone: 646-449-1311
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Olympia, Washington 98502
Principal Investigator: Joseph Ye
Phone: 3608103625
?
mi
from
Olympia, WA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
Principal Investigator: John Lister, MD
Phone: 412-578-4493
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temple, Texas 76504
Principal Investigator: Juan Posada, MD
Phone: 254-743-1226
?
mi
from
Temple, TX
Click here to add this to my saved trials